ReGenMed Group Wants Fixes To Ensure Proper Use Of Hospital Exemption In EU
Executive Summary
Advocacy group Alliance for Regenerative Medicines has called for urgent fixes to the hospital exemption scheme under the EU Advanced Therapy Medicinal Products Regulation to ensure the provision is not misused to by-pass strict marketing authorization requirements.
You may also be interested in...
Decade-Old Advanced Therapy Set For EU Approval
German company CO.DON is celebrating the fact that it probably won’t be long before it can start selling across Europe its key product – an advanced therapy for the repair of certain cartilage defects of the knee that’s been in use in Germany for ten years.
First European Cell Therapy Is Commercial Flop
The first cell-based product to be approved in Europe, the TiGenix-developed and Sobi-marketed ChondroCelect, has met an ignominious end with the withdrawal of its marketing authorization. However, TiGenix has entered into an agreement with Takeda for ex-US rights to its next product candidate.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.